Campbell & CO Investment Adviser LLC Has $476,000 Holdings in Simulations Plus, Inc. (NASDAQ:SLP)

Campbell & CO Investment Adviser LLC increased its holdings in Simulations Plus, Inc. (NASDAQ:SLP) by 5.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,320 shares of the technology company’s stock after acquiring an additional 300 shares during the period. Campbell & CO Investment Adviser LLC’s holdings in Simulations Plus were worth $476,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of SLP. US Bancorp DE grew its position in Simulations Plus by 51.8% in the 2nd quarter. US Bancorp DE now owns 987 shares of the technology company’s stock worth $59,000 after purchasing an additional 337 shares in the last quarter. Meeder Asset Management Inc. grew its position in Simulations Plus by 11,046.2% in the 1st quarter. Meeder Asset Management Inc. now owns 1,449 shares of the technology company’s stock worth $50,000 after purchasing an additional 1,436 shares in the last quarter. Teachers Retirement System of The State of Kentucky bought a new stake in Simulations Plus in the 2nd quarter worth about $90,000. USA Financial Portformulas Corp bought a new stake in Simulations Plus in the 3rd quarter worth about $195,000. Finally, FinTrust Capital Advisors LLC bought a new stake in Simulations Plus in the 1st quarter worth about $106,000. Institutional investors own 59.61% of the company’s stock.

A number of equities research analysts have issued reports on the stock. Craig Hallum upped their price objective on shares of Simulations Plus from $56.00 to $75.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Raymond James started coverage on shares of Simulations Plus in a research report on Friday. They issued an “outperform” rating and a $95.00 price objective for the company. BidaskClub downgraded shares of Simulations Plus from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, October 7th. Zacks Investment Research downgraded shares of Simulations Plus from a “buy” rating to a “hold” rating in a research report on Wednesday, September 16th. Finally, Oppenheimer started coverage on shares of Simulations Plus in a research report on Tuesday, September 8th. They set an “outperform” rating and a $79.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Simulations Plus presently has a consensus rating of “Buy” and a consensus target price of $80.00.

Simulations Plus stock opened at $72.28 on Friday. The company has a market capitalization of $1.29 billion, a P/E ratio of 144.56, a P/E/G ratio of 6.76 and a beta of -0.19. The firm has a 50 day moving average price of $66.84 and a 200-day moving average price of $54.93. Simulations Plus, Inc. has a twelve month low of $26.00 and a twelve month high of $77.89.

The firm also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Monday, October 26th will be paid a dividend of $0.06 per share. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date of this dividend is Friday, October 23rd. Simulations Plus’s payout ratio is currently 50.00%.

In related news, Director Walter S. Woltosz sold 24,000 shares of the company’s stock in a transaction that occurred on Thursday, September 24th. The shares were sold at an average price of $66.08, for a total transaction of $1,585,920.00. Following the sale, the director now directly owns 4,731,359 shares in the company, valued at approximately $312,648,202.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 28.96% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.

Featured Article: Momentum Indicator: Relative Strength Index

Want to see what other hedge funds are holding SLP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Simulations Plus, Inc. (NASDAQ:SLP).

Institutional Ownership by Quarter for Simulations Plus (NASDAQ:SLP)

Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.